Moderna has announced that the FDA will initiate the review of its seasonal influenza vaccine candidate, mRNA-1010.

Novo Nordisk and United Laboratories’ jointly developed triple G drug has achieved a 19.7% weight loss in a Phase II trial in ...

Patients with HIV showed lower cases of steatotic liver disease when switched to ViiV Healthcare’s Dovato compared to ...

C4 Therapeutics has dosed the first patient in its Phase II MOMENTUM trial of cemsidomide, an oral IKZF1/3 degrader, combined with dexamethasone for patients with RRMM.

In the trial, CagriSema appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema ...

The US Food and Drug Administration (FDA) has issued more information to sponsors regarding its “plausible mechanism pathway” ...

Jaguar Gene Therapy has completed Cohort I dosing of its first-in-human clinical trial investigating JAG201 for patients with SHANK3 haploinsufficiency.

Gossamer Bio has reported topline data from the Phase III PROSERA study evaluating seralutinib in patients with PAH.

Prasad and Makary disagree that some may believe this move to just one pivotal trial shows the FDA relaxing its standards.

ViiV Healthcare’s investigational four-monthly HIV drug maintains viral suppression at 12 months in a Phase IIb trial. In the EMBRACE trial (NCT05996471), lotivibart, a broadly neutralising antibody, ...

The therapy is constructed by the insertion of TCF4 isoform B into an AAV9 expression cassette. Credit: Stock-Asso / Shutterstock.com. Mahzi Therapeutics has dosed the first patient in its Phase I/II ...

This report follows a number of initiatives in the EU that are trying to make it a more attractive region for research. Image credit: Vladimir Sukhachev / Shutterstock.com A further €4bn ($4.72bn) a ...